GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (NAS:GLYC) » Definitions » Cyclically Adjusted PB Ratio

GLYC (GlycoMimetics) Cyclically Adjusted PB Ratio : 5.49 (As of Jul. 01, 2025)


View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics Cyclically Adjusted PB Ratio?

As of today (2025-07-01), GlycoMimetics's current share price is $15.70. GlycoMimetics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $2.86. GlycoMimetics's Cyclically Adjusted PB Ratio for today is 5.49.

The historical rank and industry rank for GlycoMimetics's Cyclically Adjusted PB Ratio or its related term are showing as below:

GLYC' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 5.02   Med: 22.48   Max: 103.13
Current: 5.48

During the past years, GlycoMimetics's highest Cyclically Adjusted PB Ratio was 103.13. The lowest was 5.02. And the median was 22.48.

GLYC's Cyclically Adjusted PB Ratio is ranked worse than
81.35% of 681 companies
in the Biotechnology industry
Industry Median: 1.5 vs GLYC: 5.48

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

GlycoMimetics's adjusted book value per share data for the three months ended in Mar. 2025 was $0.052. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.86 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


GlycoMimetics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for GlycoMimetics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics Cyclically Adjusted PB Ratio Chart

GlycoMimetics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 86.10 74.08 8.58

GlycoMimetics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.00 9.16 5.66 8.58 7.34

Competitive Comparison of GlycoMimetics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, GlycoMimetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoMimetics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's Cyclically Adjusted PB Ratio falls into.


;
;

GlycoMimetics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

GlycoMimetics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=15.70/2.86
=5.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlycoMimetics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, GlycoMimetics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.052/134.9266*134.9266
=0.052

Current CPI (Mar. 2025) = 134.9266.

GlycoMimetics Quarterly Data

Book Value per Share CPI Adj_Book
201506 2.903 100.684 3.890
201509 2.558 100.392 3.438
201512 2.125 99.792 2.873
201603 1.803 100.470 2.421
201606 2.122 101.688 2.816
201609 1.810 101.861 2.398
201612 1.518 101.863 2.011
201703 1.337 102.862 1.754
201706 3.528 103.349 4.606
201709 3.316 104.136 4.296
201712 3.484 104.011 4.520
201803 5.602 105.290 7.179
201806 5.295 106.317 6.720
201809 5.056 106.507 6.405
201812 4.760 105.998 6.059
201903 4.465 107.251 5.617
201906 4.134 108.070 5.161
201909 3.853 108.329 4.799
201912 3.548 108.420 4.415
202003 3.407 108.902 4.221
202006 3.120 108.767 3.870
202009 2.891 109.815 3.552
202012 2.616 109.897 3.212
202103 2.428 111.754 2.931
202106 2.179 114.631 2.565
202109 1.866 115.734 2.175
202112 1.560 117.630 1.789
202203 1.298 121.301 1.444
202206 1.063 125.017 1.147
202209 0.918 125.227 0.989
202212 0.789 125.222 0.850
202303 0.968 127.348 1.026
202306 0.852 128.729 0.893
202309 0.723 129.860 0.751
202312 0.597 129.419 0.622
202403 0.449 131.776 0.460
202406 0.311 132.554 0.317
202409 0.176 133.029 0.179
202412 0.082 133.157 0.083
202503 0.052 134.927 0.052

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlycoMimetics  (NAS:GLYC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


GlycoMimetics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoMimetics Business Description

Traded in Other Exchanges
Address
P.O. Box 65, Monrovia, MD, USA, 21770
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Executives
Invus Public Equities, L.p. 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Edwin Rock officer: Chief Medical Officer 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Brian M. Hahn officer: CFO C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Daniel M Junius director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Bruce S Johnson officer: SVP & Chief Commercial Officer 9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850
Chinmaya Rath officer: SVP and Chief Business Officer 9708 MEDICAL CENTER DR., ROCKVILLE MD 20850
Invus Public Equities Advisors, Llc 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Artal Group S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
S.a. Westend 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Administratiekantoor Westend Stichting 10 percent owner CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD
Artal International Management S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Amaury Wittouck 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661
Scott D Sandell 10 percent owner
Harout Semerjian director, officer: Chief Executive Officer 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950